Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live
Company

Palisade Bio

Tracked across 1 events · 6 articles · First seen Sep 23, 2026 · Last active Sep 23, 2026

Sentiment
10
Attention
1
Events
1
Relationships
0
Live sentiment trends, attention charts, and prominence tracking available on the Ergen Dashboard
1 10
Regulatory
Palisade Bio, Inc. (Nasdaq: PALI) announced that Canada — Health Canada has cleared its Clinical Trial Application (CTA) for ASCENTRA-UC, a global Phase 2 study evaluating PALI-2108 in patients with moderately to severely active ulcerative…
Impact: Palisade Bio is the central entity of this event, receiving Canada — Health Canada clearance for its ASCENTRA-UC Phase 2 trial of PALI-2108, which expands the study into Canada and supports planned enrollment. The clearance is a positive execution milestone but shares traded down 2.96% at $1.64, indicating limited near-term market impact.
Sep 23, 2026 · 6 articles
90 Canada — Health Canada cleared clinical trial application Palisade BioHealth Canada Clears...
ERGEN INTELLIGENCE
Track Palisade Bio live

Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.